Radisens’ disruptive diagnostics platform introduces HDR™ and AirSpring™ technologies to realise a single device, and multiple multiplexed assay panels, which require only a drop of patient’s blood for instant sample-to-answer lab-grade results.
Radisens’ Gemini™ platform, which includes myriad nanotechnology breakthroughs, has been realised by our multidisciplinary biochemistry, centrifugal microfluidics, optoelectronics and manufacturing process development teams. Our multiple patent-pending innovations integrate multiplexed immunoassay, clinical chemistry, haematology and turbidimetry technologies onto one diagnostic device for integrated point-of-care operation.
This multi-mode approach introduces new paradigms for the diagnosis and monitoring of chronic disease co-morbidity, introducing stepped improvements for the chronic disease management. With demonstrated ‘third generation’ performance, a fraction of a blood drop delivers instant diagnostic results. Initial test panels target the diabetes, heart disease, chronic kidney and liver disease clinical pathways.
With better than 2pg/ml (TSH) sensitivities, this quantitative diagnostics platform finally brings central laboratory performance to point-of-care settings, without the need for large capital outlay, complex quality assurance or training programmes, or complicated operator protocols.
Chronic Disease Co-Morbidity Test Menu
Initial test panels for improved chronic disease co-morbidity management include:
- Chronic Diabetes (HbA1c)
- Heart Disease (Full lipids)
- Thyroid Function (3rd generation TSH)
- Renal Function (Creatinine, Electrolytes)
- Complete Blood Count (CBC w/ 5pt diff)
- … plus an extensive panel roadmap
For more details please visit: http://www.radisens.com/
Comments are closed.